Publications by authors named "Guenter Henze"

Claim this Profile
P
Prognostic impact and clinical value of low levels of flow cytometric MRD at the end of induction in childhood B-lineage acute lymphoblastic leukemia: Results of study ALL-MB 2015.
Alexander Popov, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Ekaterina Mikhailova

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study.
Eleni A Argyriadi, Ingo G Steffen, Christiane Chen-Santel, Andrej Lissat, Andishe Attarbaschi, Guenter Henze

Leukemia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
Ekaterina Mikhailova, Alexander Popov, Julia Roumiantseva, Oleg Budanov, Svetlana Lagoyko, Guenter Henze

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Alexander Popov, Guenter Henze, Grigory Tsaur, Oleg Budanov, Julia Roumiantseva

Cancer Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial.
Larisa Fechina, Alexander Popov, Grigory Tsaur, Guenter Henze, Egor Shorikov

Leukemia· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study.
Alexander Popov, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Mikhail Belevtsev

J Cancer Res Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement.
Alexander Popov, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Mikhail Belevtsev

Pediatr Blood Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
Alexander Popov, Grigory Tsaur, Zhan Permikin, Guenter Henze, Tatiana Verzhbitskaya

Pediatr Blood Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
Alexander Popov, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Tatiana Verzhbitskaya

Leuk Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
Alexander Popov, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Mikhail Belevtsev

Leuk Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.
Felix Schriegel, Sabine Taschner-Mandl, Marie Bernkopf, Uwe Grunwald, Nikolai Siebert, Guenter Henze

J Cancer Res Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simple algorithm with one flow cytometric MRD measurement identifies more than 40% of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results.
Alexander Popov, Guenter Henze, Julia Roumiantseva, Oleg Budanov, Mikhail Belevtsev

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Ekaterina Mikhailova, Julia Roumiantseva, Olga Illarionova, Svetlana Lagoyko, Natalia Miakova, Guenter Henze

Br J Haematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group.
Andrej Lissat, Claudia van Schewick, Ingo G Steffen, Ayumu Arakawa, Jean-Pierre Bourquin, Guenter Henze

J Clin Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
Cornelia Eckert, Catriona Parker, Anthony V Moorman, Julie Ae Irving, Renate Kirschner-Schwabe, Guenter Henze

Eur J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma.
Karoline Ehlert, Ina Hansjuergens, Andreas Zinke, Sylke Otto, Nikolai Siebert, Guenter Henze

J Immunother Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia.
Alexander Popov, Guenter Henze, Tatiana Verzhbitskaya, Julia Roumiantseva, Svetlana Lagoyko

J Cancer Res Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB).
Yulia Olshanskaya, Anna Kazakova, Grigory Tsaur, Elena Zerkalenkova, Olga Soldatkina, Guenter Henze

Leuk Lymphoma· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age at menarche in childhood cancer survivors: results of a nationwide survey in Germany.
Theda Wessel, Magdalena Balcerek, Simone Reinmuth, Cynthia Hohmann, Thomas Keil, Guenter Henze

Horm Res Paediatr· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First case report of a peripheral T-cell lymphoma, not otherwise specified, of the central nervous system in a child.
Maria Lueth, Harald Stein, Birgit Spors, Guenter Henze, Pablo Hernáiz Driever

J Pediatr Hematol Oncol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient counselling on the risk of infertility and its impact on childhood cancer survivors: results from a national survey.
Cynthia Hohmann, Anja Borgmann-Staudt, Rosa Rendtorff, Simone Reinmuth, Steve Holzhausen, Guenter Henze

J Psychosoc Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiproliferative effect of the serotonin receptor antagonist ondansetron in the acute lymphoblastic leukemia cell line REH.
Javier Prada, Shabnam Shalapour, Madlen Pfau, Guenter Henze, Karl Seeger

Acta Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells.
Mona Tamannai, Sonja Farhangi, Matthias Truss, Brigitte Sinn, Reinhard Wurm, Guenter Henze

Oncol Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region.
Maria Lueth, Andreas von Deimling, Torsten Pietsch, Lee-Jun Wong, Andreas Kurtz, Guenter Henze

J Pediatr Hematol Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells.
Gesche Tallen, Sonja Farhangi, Mona Tamannai, Nikola Holtkamp, Dorothea Mangoldt, Guenter Henze

Oncol Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis